Search details
1.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat
; 156(1): 81-9, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26909792
2.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Breast Cancer Res
; 16(2): R38, 2014 Apr 12.
Article
in English
| MEDLINE | ID: mdl-24725534
3.
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Int J Cancer
; 132(5): 1090-7, 2013 Mar 01.
Article
in English
| MEDLINE | ID: mdl-22833293
4.
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
BMC Cancer
; 12: 456, 2012 Oct 05.
Article
in English
| MEDLINE | ID: mdl-23039280
5.
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
PLoS One
; 12(9): e0183917, 2017.
Article
in English
| MEDLINE | ID: mdl-28877230
6.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
J Natl Cancer Inst
; 108(11)2016 11.
Article
in English
| MEDLINE | ID: mdl-27400969
7.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Microarrays (Basel)
; 2(3): 243-64, 2013 Aug 29.
Article
in English
| MEDLINE | ID: mdl-27605191
8.
Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.
J Clin Pathol
; 65(7): 660-2, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22447922
9.
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Virchows Arch
; 460(3): 251-9, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-22371223
10.
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
Diagn Mol Pathol
; 20(1): 1-10, 2011 Mar.
Article
in English
| MEDLINE | ID: mdl-21326033
Results
1 -
10
de 10
1
Next >
>>